HR Execs on the Move

Inozyme

www.inozyme.com

 
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.inozyme.com
  • 321 Summer Street Suite 400
    Boston, MA USA 02210
  • Phone: 857.330.4340

Executives

Name Title Contact Details
Gayle Gironda
 Senior Vice President of Human Resources Profile
Axel Bolte
 Chief Executive Officer Profile

Similar Companies

Celerion Inc

Celerion Inc is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

STERIS

STERIS is the world's pre-eminent infection prevention, decontamination, and surgical and critical care company, with a long list of first-to-market products and industry-leading service innovations and thousands of customers in more than 60 countries.

Vital Probes Inc

Vital Probes Inc is a Jermyn, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stuart Therapeutics

Stuart Therapeutics was established in 2017 for the development and commercialization of PolyCol, a versatile therapeutic platform that offers a unique tissue reparative approach to a variety of ophthalmic disease indications.

Sapience Therapeutics

Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme (GBM), which is the most severe and deadly form of brain cancer.